Olaparib dose reduction in BRCA-mutated platinum-sensitive ovarian cancer recurrence: real-world data

This publication has 19 references indexed in Scilit:

• Association Between BRCA1 And BRCA2 Mutations With Toxicity From Olaparib In Platinum Sensitive Relapsed High Grade Ovarian Cancer
  International Journal of Gynecological Cancer, 2025
• Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights
  ESMO Open, 2024
• HRD testing for all advanced high-grade ovarian carcinoma in first line?
  ESMO Open, 2024
• PARP inhibitors: enhancing efficacy through rational combinations
  British Journal of Cancer, 2023
• The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
  Annals of Oncology, 2022
• ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
  Annals of Oncology, 2020
• Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study
  Targeted Oncology, 2018
• Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
  The Lancet Oncology, 2017
• Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer
  Gynecologic Oncology, 2017
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009